The CD19-targeting BiTE (blinatumomab) was the first to be approved for cancer therapy after showing remarkable response rates of almost 70% in CD19-positive, relapsed/refractory (R/R) hematological malignancies. This evidence concerns the gene CD19 and hematologic disorder.